UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How does technological progress promote carbon productivity? Evidence from Chinese manufacturing industries

Journal of environmental management, 2021-01, Vol.277, p.111325-111325, Article 111325

2021

Volltextzugriff (PDF)

How heterogeneous technological progress promotes industrial structure upgrading and industrial carbon efficiency? Evidence from China's industries

Energy (Oxford), 2022-05, Vol.247, p.123386, Article 123386

2022

Volltextzugriff (PDF)

Addressing Social Determinants of Mental Health in Pediatrics during the COVID-19 Pandemic

Academic pediatrics, 2022-11

2022

Volltextzugriff (PDF)

5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S13

2024

Volltextzugriff (PDF)

Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S12-S13

Serzan, Michael

2024

Volltextzugriff (PDF)

19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S14

Msaouel, Pavlos

2024

Volltextzugriff (PDF)

75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S16

2024

Volltextzugriff (PDF)

45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S15

2024

Volltextzugriff (PDF)

29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Suppl 1), p.S14-S15

2024

Volltextzugriff (PDF)

OBLIGACIONES DE INFORMACIÓN RELATIVAS A MONEDAS VIRTUALES EN EL ÁMBITO NACIONAL

Dereito (Santiago de Compostela), 2023-09, Vol.32 (1)

Taboada Villa, Jorge

2023

Volltextzugriff (PDF)

Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry

The Journal of biological chemistry, 2024-03, Vol.300 (3), p.105924, Article 105924

2024

Volltextzugriff (PDF)

The feelings of progress: peripheral temporalities during late socialism

Canadian Slavonic papers, 2023-01, Vol.65 (1), p.1-6

2023

Volltextzugriff (PDF)

The Scottish Enlightenment: Race, Gender, and the Limits of Progress

Sebastiani, Silvia

1, 2013

Volltextzugriff (PDF)

A review of successful climate change mitigation policies in major emitting economies and the potential of global replication

Renewable & sustainable energy reviews, 2021-03, Vol.137, p.110602, Article 110602

2021

Volltextzugriff (PDF)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S14

2023

Volltextzugriff (PDF)

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S11

2023

Volltextzugriff (PDF)

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S12

Chouieri, Toni

2023

Volltextzugriff (PDF)

Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S10-S11

2023

Volltextzugriff (PDF)

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S13

2023

Volltextzugriff (PDF)

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S14-S15

2023

Volltextzugriff (PDF)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S14-S14

2023

Volltextzugriff (PDF)

NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S13

McKay, Rana

2023

Volltextzugriff (PDF)

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S12

2023

Volltextzugriff (PDF)

DAS SUPERHIRN

Politische Studien, 2020-07, Vol.71 (492), p.52-62

Balleis, Siegfried

2020

Volltextzugriff (PDF)

Zurück Zum Fortschritt: Deutungsmacht und Die Wende Zum Möglichen

Hastedt, Heiner

1, 2023

Volltextzugriff (PDF)

1 – 25 von 43.814

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23.870)
Mit Volltextzugriff
(35.180)

Publikationsform

10 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(40.533)
Französisch
(1.612)
Japanisch
(1.428)
Spanisch
(635)
Deutsch
(508)
Chinesisch
(443)
Portugiesisch
(380)
Russisch
(189)
Italienisch
(90)
Croatian
(72)
Polnisch
(48)
Türkisch
(40)
Tschechisch
(25)
Niederländisch
(25)
Rumänisch
(24)
Arabisch
(22)
Ungarisch
(20)
Norwegisch
(19)
Serbian
(15)
Koreanisch
(14)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(11.298)
Ingenta Connect
(11.038)
Jstor Complete Legacy
(7.919)
Ebook Central Perpetual and DDA
(6.027)
eBooks on EBSCOhost
(5.440)
IngentaConnect Journals
(5.417)
ERIC
(4.721)
EBSCOhost Business Source Ultimate
(4.628)
Springer Nature - Complete Springer Journals
(3.939)
Publisher or Other Site
(3.916)
MEDLINE
(3.896)
Sociological Abstracts
(3.741)
Journals@Ovid Complete
(3.139)
Elsevier ScienceDirect Journals Complete
(2.972)
Wiley Online Library Journals Frontfile Complete
(2.834)
PAIS Index
(2.733)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.613)
Taylor & Francis Current Content Access
(2.378)
Taylor & Francis:Master (3349 titles)
(2.313)
Nexis Uni
(2.276)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Scientific Monthly
(1.403)
International Journal Of Hematology
(447)
Psychological Studies
(344)
The American Scholar
(342)
Social Indicators Research
(254)
The Geographical Journal
(201)
Corn And Soybean Digest
(163)
Monthly Labor Review
(140)
Journal Of Dairy Research
(135)
Revue Neurologique
(135)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

How does technological progress promote carbon productivity? Evidence from Chinese manufacturing industries

How heterogeneous technological progress promotes industrial structure upgrading and industrial carbon efficiency? Evidence from China's industries

Addressing Social Determinants of Mental Health in Pediatrics during the COVID-19 Pandemic

5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)

19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma

75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)

OBLIGACIONES DE INFORMACIÓN RELATIVAS A MONEDAS VIRTUALES EN EL ÁMBITO NACIONAL

Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry

The feelings of progress: peripheral temporalities during late socialism

The Scottish Enlightenment: Race, Gender, and the Limits of Progress

A review of successful climate change mitigation policies in major emitting economies and the potential of global replication

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma

Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

DAS SUPERHIRN

Zurück Zum Fortschritt: Deutungsmacht und Die Wende Zum Möglichen

Suchergebnisse filtern